Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

FDA Alerts

Alopecia Areata, blad head
FDA Alerts
Deuruxolitinib FDA Approved for Severe Alopecia Areata in Adults
07/30/2024
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved...
07/30/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.15% for Treatment of Atopic Dermatitis in Adults and Children Aged 6 and Older
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug...
07/09/2024
The Dermatologist
AD
FDA Alerts
FDA Approves Tralokinumab Autoinjector for Adults with Moderate-to-Severe Atopic Dermatitis
06/15/2024
Riya Gandhi, MA, Associate Editor
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug Administration has approved a new Adbry (tralokinumab-ldrm) 300 mg single-dose autoinjector, offering a new administration option for adult patients with moderate-to-severe atopic dermatitis.
The US Food and Drug...
06/15/2024
The Dermatologist
Actinic Keratosis
FDA Alerts
FDA Approves Almirall’s Klisyri for Expanded Treatment Area of Actinic Keratosis
06/11/2024
Riya Gandhi, MA, Associate Editor
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug Administration (FDA) has recently approved an expansion for the use of Klisyri (tirbanibulin) to treat actinic keratosis (AK) on larger areas of the face or scalp, up to 100 cm².
The US Food and Drug...
06/11/2024
The Dermatologist
Atopic Derm
FDA Alerts
Dupixent Receives Expanded FDA Approval for Atopic Dermatitis with Moderate to Severe Hand and Foot Involvement
01/19/2024
Riya Gandhi, MA, Associate Editor
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an update to the label for Dupixent (dupilumab) for atopic dermatitis for patients ages 12 years and older with AD and uncontrolled moderate to severe involvement of the hands and/or feet.
The US FDA has approved an...
01/19/2024
The Dermatologist
atopic dermatitis
FDA Alerts
Tralokinumab-ldrm Approved for Treatment of Moderate to Severe Atopic Dermatitis in Pediatric Patients
12/18/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug Administration recently announced approval of tralokinumab-ldrm (Adbry) to include pediatric patients aged 12 to 17 years with moderate to severe atopic dermatitis.
The US Food and Drug...
12/18/2023
The Dermatologist
Roflumilast Topical Foam
FDA Alerts
Roflumilast Topical Foam, 0.3% Approved for Treatment of Seborrheic Dermatitis
12/18/2023
Jessica Garlewicz, Digital Managing Editor
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for seborrheic dermatitis with a new mechanism of action in over 2 decades, roflumilast foam, 0.3% is indicated for treatment of seborrheic dermatitis in adult and pediatric patients.
As the first drug approved for...
12/18/2023
The Dermatologist
FDA Alerts
Secukinumab Approved as New Biologic Treatment Option for Hidradenitis Suppurativa
11/01/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug Administration recently announced approval of Cosentyx (secukinumab) for the treatment of hidradenitis suppurativa.
The US Food and Drug...
11/01/2023
The Dermatologist
psoriasis
FDA Alerts
Bimekizumab-bkzx Approved for Adults With Moderate to Severe Plaque Psoriasis
10/19/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of bimekizumab-bkzx for the treatment of adults with moderate to severe plaque psoriasis.
The US Food and Drug Administration recently announced approval of bimekizumab-bkzx for the treatment of adults with moderate to severe plaque psoriasis.
The US Food and Drug...
10/19/2023
The Dermatologist
FDA Alerts
Nivolumab Approved as Adjuvant Treatment for Patients With Completely Resected Stage IIB or Stage IIC Melanoma
10/19/2023
Jessica Garlewicz, Digital Managing Editor
The US Food and Drug Administration recently announced approval of nivolumab as an adjuvant treatment for eligible patients with stage IIB or IIC completely resected melanoma.
The US Food and Drug Administration recently announced approval of nivolumab as an adjuvant treatment for eligible patients with stage IIB or IIC completely resected melanoma.
The US Food and Drug...
10/19/2023
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Current Issue

August 2024
Volume 32
Issue 5
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Popular Articles
Feature Story
Tips for Preventing Further Skin Irritation with Adult AD
06/04/2018
Lindsay Strowd, MD
Personal care products and fabrics can be a major source of potential irritation for people living with atopic dermatitis. In this exclusive series on Tips for Improving Adult Atopic Dermatitis, Lindsay C. Strowd, MD, discusses tips for...
Personal care products and fabrics can be a major source of potential irritation for people living with atopic dermatitis. In this exclusive series on Tips for Improving Adult Atopic Dermatitis, Lindsay C. Strowd, MD, discusses tips for...
Personal care products and...
06/04/2018
The Dermatologist
Cover Story
ICD-10: What a Physician Needs to Know
09/06/2012
The United States will soon be joining much of Europe, Canada and Australia with the use of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). The ICD-10 includes about five times as...
The United States will soon be joining much of Europe, Canada and Australia with the use of the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). The ICD-10 includes about five times as...
The United States will soon be...
09/06/2012
The Dermatologist
News
HMP’s The Dermatologist Partners With George Washington School of Medicine & Health Sciences Department of Dermatology
08/10/2020
The Dermatologist®, has formed a collaborative partnership with George Washington School of Medicine & Health Sciences, Department of Dermatology.
The Dermatologist®, has formed a collaborative partnership with George Washington School of Medicine & Health Sciences, Department of Dermatology.
The Dermatologist®, has formed a...
08/10/2020
The Dermatologist
Anti-Interleukin 17 Agents Show Promise for Psoriasis in Clinical Trials
05/03/2012
Three anti-interleukin-17 biologics are in development for psoriasis that have shown promise in Phase II trials. IL-17 is produced by neutrophils, mast cells and CD4+ and CD8+ T cells, and the two isoforms of IL-17, IL-17A and IL-17F, are...
Three anti-interleukin-17 biologics are in development for psoriasis that have shown promise in Phase II trials. IL-17 is produced by neutrophils, mast cells and CD4+ and CD8+ T cells, and the two isoforms of IL-17, IL-17A and IL-17F, are...
Three anti-interleukin-17...
05/03/2012
The Dermatologist
Podcasts
Conversations With Dr Barankin: Seemal Desai, MD
08/05/2020
In this podcast series, Benjamin Barankin, MD, interviews leaders in dermatology about their lives, their wisdom, and any easy, actionable tips for balancing life as a busy dermatologist. This first episode features Seemal Desai, MD.
In this podcast series, Benjamin Barankin, MD, interviews leaders in dermatology about their lives, their wisdom, and any easy, actionable tips for balancing life as a busy dermatologist. This first episode features Seemal Desai, MD.
In this podcast series, Benjamin...
08/05/2020
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

The Dermatologist Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Latest Quizzes and Trivia

Quiz
QUIZ: Topical PDE-4 Inhibitors For Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
08/10/2024
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola...
08/10/2024
The Dermatologist
contact dermtitis + Neck + Eczema + rash
Quiz
QUIZ: Patient Experiences in Contact Dermatitis and Patch Testing
07/14/2024
What is a common challenge for patients during the patch testing week?
What is a common challenge for patients during the patch testing week?
What is a common challenge for...
07/14/2024
The Dermatologist
gloves hands
Quiz
Quiz: Barrier to Mental Health Support in Patients with Atopic Dermatitis
05/30/2024
Riya Gandhi, MA, Associate Editor
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview with Jessica Johnson, MPH, what is a significant barrier to seeking mental health support among patients with atopic dermatitis?
According to a recent interview...
05/30/2024
The Dermatologist
Atopic dermatitis
Quiz
Quiz: Atopic Dermatitis Spotlight
05/06/2024
Riya Gandhi, MA, Associate Editor
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications received a "general thumbs up" in the latest guidelines for atopic dermatitis management due to their efficacy and low cancer risk?
Which class of medications...
05/06/2024
The Dermatologist
basal cell carcinoma
Quiz
True or False: Basal Cell Carcinoma on Vermilion Lip
05/01/2024
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the vermilion lip a distinctly rare phenomenon, sparsely documented in existing literature?
Is basal cell carcinoma on the...
05/01/2024
The Dermatologist
Atopic Dermatitis + Eczema + Itch + Rash + Kids + Legs + Elbow + Knee
Quiz
Quiz: Navigating New Therapies in Atopic Dermatitis
04/10/2024
Riya Gandhi, MA, Associate Editor
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
In a recent interview, Dr Jonathan Silverberg, mentioned the importance of understanding the strengths and weaknesses of new therapies. Which aspect did he particularly emphasize as crucial in clinical practice?
In a recent interview, Dr...
04/10/2024
The Dermatologist
AD
Quiz
Trivia: Atopic Dermatitis Patients With Alopecia Areata
02/28/2024
Riya Gandhi, MA, Associate Editor
02/28/2024
The Dermatologist
AD
Quiz
Trivia: Itch Cycle and OTC Products
12/27/2023
12/27/2023
The Dermatologist
psoriasis
Quiz
Trivia: Recommended Treatment For Psoriasis
12/20/2023
Jessica Garlewicz, Digital Managing Editor
When treating mild to moderate and moderate to severe plaque psoriasis, what is the recommended treatment?
When treating mild to moderate and moderate to severe plaque psoriasis, what is the recommended treatment?
When treating mild to moderate...
12/20/2023
The Dermatologist
Ilka Arun Netravali, MD, PhD, FAAD
Quiz
Dupilumab Mechanism of Action
11/07/2023
Jessica Garlewicz, Digital Managing Editor
According to a recent interview with Dr Ilka Arun Netravali, what is the mechanism of action behind dupilumab that translates to effective suppression of atopic disease?
According to a recent interview with Dr Ilka Arun Netravali, what is the mechanism of action behind dupilumab that translates to effective suppression of atopic disease?
According to a recent interview...
11/07/2023
The Dermatologist

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement